Please Wait
Applying Filters...
menu
    • menu
    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Inke S.A: APIs manufacturing plant.

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-08-11

    Virtual Booth

    An Enquiry

    Menu

    Filgotinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 16,639Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alfasigma's JAK Inhibitor Jyseleca Scores in Phase 3 Trial
    Alfasigma's JAK Inhibitor Jyseleca Scores in Phase 3 Trial

    30 Jul 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/alfasigma-touts-results-phase-3-trial-former-galapagos-jak-inhibitor-jyseleca

    FIERCE PHARMA
    30 Jul 2025
    Share Share
    Filgotinib Shows Results in Axial Spondyloarthritis Phase 3 Study
    Filgotinib Shows Results in Axial Spondyloarthritis Phase 3 Study

    28 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250728902063/en/Filgotinib-Shows-Positive-Topline-Results-Across-Full-Spectrum-of-Axial-Spondyloarthritis-in-OLINGUITO-Phase-3-Study

    BUSINESSWIRE
    28 Jul 2025
    Share Share
    Galapagos announces first quarter 2023 financial results
    Galapagos announces first quarter 2023 financial results

    04 May 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/05/04/2661990/0/en/Galapagos-announces-first-quarter-2023-financial-results.html

    GLOBENEWSWIRE
    04 May 2023
    Share Share
    Galapagos initiates Phase 3 program with filgotinib in patients with AAS
    Galapagos initiates Phase 3 program with filgotinib in patients with AAS

    26 Apr 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/04/26/2655620/0/en/Galapagos-initiates-Phase-3-program-with-filgotinib-in-patients-with-active-axial-spondyloarthritis.html

    GLOBENEWSWIRE
    26 Apr 2023
    Share Share
    Galapagos announces results from PIII trial of filgotinib in Crohn’s disease
    Galapagos announces results from PIII trial of filgotinib in Crohn’s disease

    09 Feb 2023

    // PRESS RELEASE

    https://www.glpg.com/press-release/3766/galapagos-announces-topline-results-from-phase-3-diversity-trial-of-filgotinib-in-crohn-s-disease

    PRESS RELEASE
    09 Feb 2023
    Share Share
    EMA backs restrictions on certain immune-regulating drugs
    EMA backs restrictions on certain immune-regulating drugs

    12 Nov 2022

    // BIOPHARMADIVE

    https://www.biopharmadive.com/news/ema-recommends-jak-inhibitors-restrictions/636343/

    BIOPHARMADIVE
    12 Nov 2022
    Share Share